Avalyn Pharma Acquisition | Healthcare Deal in NY

Avalyn Pharma has completed the IPO of Avalyn Pharma, a healthcare services other business in New York, for $345 million. The clinical-stage biopharmaceutical company develops inhaled therapies aimed at serious, rare respiratory diseases, supporting healthcare M&A interest in respiratory-focused platforms and other acquisition strategies. With common stock listed on Nasdaq Global Select Market under ticker AVLN, the offering closed in May 2026 after the full exercise of the underwriters’ overallotment option for 2,500,000 additional shares at $18.00 per share. The healthcare deals NY capital raise involved joint book-running managers including Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities, with all shares sold by Avalyn as part of an other acquisition financing.